viloxazine · Qelbree
Small molecule
Evidence outlook
Approved: Attention Deficit Hyperactivity Disorder
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT03247530 NCT03247530 · ADHD This was a randomized, quadruple-blind, placebo-controlled trial with 477 enrolled participants, and the primary analysis included 155 placebo, 147 participants receiving 100 mg, and 158 receiving 200 mg. The prespecified clinical primary endpoint, change in ADHD-RS-5 total score at Week 6, was significantly better with both viloxazine doses than placebo (p=0.0004 and p<0.0001). Registry: NCT03247530 | 3 | Efficacy of SPN-812 Assessed by Attention-Deficit/Hyperactivity Disorder (ADHD) Rating Scale, 5th Edition (ADHD-RS-5) (Baseline and Week 6 (End of Study)) 2018-09-12 | Efficacy of SPN-812 Assessed by Attention-Deficit/Hyperactivity Disorder (ADHD) Rating Scale, 5th Edition (ADHD-RS-5) (Baseline and Week 6 (End of Study)): Placebo -10.9 score on a scale (Standard Error 1.14) | 100mg SPN-812 -16.6 score on a scale (Standard Error 1.16) | 200mg SPN-812 -17.7 score on a scale (Standard Error 1.12) | Reliable signal | link ↗ |
View 3 more trials
NCT04016779 NCT04016779 · Attention-Deficit/Hyperactivity Disorder (ADHD) This was a randomized, quadruple-blind, placebo-controlled trial with 374 participants. The prespecified primary clinical symptom endpoint was met: AISRS scores improved more with viloxazine than placebo, with a between-group difference of -3.7 points and p=0.0040. Registry: NCT04016779 | 3 | Efficacy of SPN-812 on Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) as Assessed by the Adult ADHD Investigator Symptom Rating Scale (AISRS) Total Score (Baseline and Week 6) 2020-10-10 | Efficacy of SPN-812 on Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) as Assessed by the Adult ADHD Investigator Symptom Rating Scale (AISRS) Total Score (Baseline and Week 6): Placebo -11.7 units on a scale (Standard Error 0.9) | SPN-812 -15.5 units on a scale (Standard Error 0.91) | Reliable signal | link ↗ |
NCT03247543 NCT03247543 · ADHD The trial randomized children to viloxazine 200 mg, viloxazine 400 mg, or placebo and used quadruple masking (double-blind), with 301 participants in the primary analysis. The primary clinical symptom endpoint, change in ADHD-RS-5 total score at Week 8, was statistically significantly better with both viloxazine doses than placebo. Registry: NCT03247543 | 3 | Efficacy of SPN-812 Assessed by Attention-Deficit/Hyperactivity Disorder Rating Scale, 5th Edition (ADHD-RS-5) (Baseline and Week 8 (End of Study)) 2018-10-17 | Efficacy of SPN-812 Assessed by Attention-Deficit/Hyperactivity Disorder Rating Scale, 5th Edition (ADHD-RS-5) (Baseline and Week 8 (End of Study)): Placebo -11.7 units on a scale (Standard Error 1.48) | 200mg SPN-812 -17.6 units on a scale (Standard Error 1.43) | 400mg SPN-812 -17.5 units on a scale (Standard Error 1.52) | Reliable signal | link ↗ |
NCT03247517 NCT03247517 · Attention Deficit Hyperactivity Disorder Randomized, quadruple-blind and placebo-controlled in 310 adolescents, with a sample size calculated for the primary measure and met. ADHD symptom scores fell significantly more with viloxazine than placebo at week 6, at both 200 mg (difference -4.5, p=0.0232) and 400 mg (difference -5.1, p=0.0091). Registry: NCT03247517 | 3 | Efficacy of SPN-812 Assessed by Attention-Deficit/Hyperactivity Disorder Rating Scale, 5th Edition (ADHD-RS-5) (Baseline and Week 6 (End of Study)) 2018-10-17 | Change in ADHD-RS-5 total score at week 6: viloxazine ER 200 mg -16.0 and 400 mg -16.5 vs placebo -11.4; differences -4.5 (95% CI -8.4 to -0.6), p=0.0232, and -5.1 (95% CI -8.9 to -1.3), p=0.0091 (CT.gov posted results). | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (1)
What this study did
Phase 1/2 (1)
What this study did
Phase 4 (4)
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other norepinephrine transporter drugs
Esreboxetine, Reboxetine. Compare all 3 norepinephrine transporter drugs
3 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Attention Deficit Hyperactivity Disorder: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Viloxazine (Qelbree): this drug | Approved | Small molecule | norepinephrine transporter | Reliable signal | NCT04016779: Efficacy of SPN-812 on Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) as Assessed by the Adult ADHD Investigator Symptom Rating Scale (AISRS) Total Score (Baseline and Week 6): Placebo -11.7 units on a scale (Standard Error 0.9) | SPN-812 -15.5 units on a scale (Standard Error 0.91) NCT03247543: Efficacy of SPN-812 Assessed by Attention-Deficit/Hyperactivity Disorder Rating Scale, 5th Edition (ADHD-RS-5) (Baseline and Week 8 (End of Study)): Placebo -11.7 units on a scale (Standard Error 1.48) | 200mg SPN-812 -17.6 units on a scale (Standard Error 1.43) | 400mg SPN-812 -17.5 units on a scale (Standard Error 1.52) | |
| Centanafadine (Simtriyo) | Approved | Small molecule | Serotonin/norepinephrine/dopamine transporter | Reliable signal | NCT05257265: ADHD-RS-5 change at week 6: -18.50 [0.93] centanafadine 328.8 mg vs -14.15 [0.93] placebo (p = .0006); 164.4 mg did not meet the primary endpoint | |
| Esreboxetine | Phase 3(overall) | Small molecule | norepinephrine transporter | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Reboxetine | Phase 3(overall) | Small molecule | norepinephrine transporter | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Solriamfetol (Sunosi) | Phase 3 | Small molecule | Dopamine/norepinephrine transporter | not yet graded | No reviewed efficacy summary in this indication | |
| Lysergide Tartrate (LSD) (DT120) | Phase 2 | Small molecule | 5-HT2A receptor | not yet graded | No reviewed efficacy summary in this indication | |
| PDC-1421 | Phase 2 | Botanical | Polygalae radix extract (active components: tenuifolin, polygalasaponins, etc.) | not yet graded | No reviewed efficacy summary in this indication | |
| Ampreloxetine (TD-9855) | Discontinued | Small molecule | norepinephrine transporter | Partial signal(overall) | No reviewed efficacy summary in this indication |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Qelbree (viloxazine) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.